Virulence | sciencenewsnet.in

Breaking News

Future Parents More Likely to Get RSV Vaccine When Pregnant if Aware That RSV Can Be a Serious Illness in Infants

Transforming Agriculture and Medicine: The Impact of Gene-Based Breeding (GBB)

ADDMAN Secures Qualification Project for CuNi Submarine Fittings with the US Navy

It’s easier now to treat opioid addiction with medication — but use has changed little

Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease

A new report from the American Lung Association shows nearly 40% of people across the U.S. are living in areas that are heavily polluted.

Five facilities at Argonne where climate solutions are front and center

For Immigrants to Canada, Risk of MS Increases with Proportion of Life Spent There

Use of Acid Reflux Drugs Linked to Higher Risk of Migraine

Sweet potato quality analysis is enhanced with hyperspectral imaging and AI

25 Apr, 2024

Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses

September 23, 2020 sarah JonasResearch Results

Molecular analysis of COVID-19’s powerful second wave in Houston shows a mutated virus strain linked to higher transmission and infection rates than the coronavirus strains that caused Houston’s first wave. Gene sequencing results from 5,085 COVID-positive patients tested at Houston Methodist since early March show a virus capable of adapting, surviving and thriving – making it more important than ever for physician scientists to understand its evolution as they work to discover effective vaccines and therapies.

Study finds COVID plasma therapy safe, with 76% patients improving

May 13, 2020 sarah JonasResearch Results

The first convalescent plasma transfusion trial results from Houston Methodist have been released. Of the 25 patients in the study, 19 have improved and 11 have been discharged. With no adverse side effects caused by the therapy, the study concluded that convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the largest cohort assessed for outcomes related to convalescent plasma therapy for COVID-19.